Saltar al contenido
Merck

ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome.

Nature structural & molecular biology (2011-06-15)
Shigeki Iwase, Bin Xiang, Sharmistha Ghosh, Ting Ren, Peter W Lewis, Jesse C Cochrane, C David Allis, David J Picketts, Dinshaw J Patel, Haitao Li, Yang Shi
RESUMEN

ATR-X (alpha-thalassemia/mental retardation, X-linked) syndrome is a human congenital disorder that causes severe intellectual disabilities. Mutations in the ATRX gene, which encodes an ATP-dependent chromatin-remodeler, are responsible for the syndrome. Approximately 50% of the missense mutations in affected persons are clustered in a cysteine-rich domain termed ADD (ATRX-DNMT3-DNMT3L, ADD(ATRX)), whose function has remained elusive. Here we identify ADD(ATRX) as a previously unknown histone H3-binding module, whose binding is promoted by lysine 9 trimethylation (H3K9me3) but inhibited by lysine 4 trimethylation (H3K4me3). The cocrystal structure of ADD(ATRX) bound to H3(1-15)K9me3 peptide reveals an atypical composite H3K9me3-binding pocket, which is distinct from the conventional trimethyllysine-binding aromatic cage. Notably, H3K9me3-pocket mutants and ATR-X syndrome mutants are defective in both H3K9me3 binding and localization at pericentromeric heterochromatin; thus, we have discovered a unique histone-recognition mechanism underlying the ATR-X etiology.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-trimetil-histona H3 (Lys9), Upstate®, from rabbit
Sigma-Aldrich
Anti-dimethyl-Histone H3 (Lys9) Antibody, Upstate®, from rabbit
Sigma-Aldrich
Anti-HP1α Antibody, clone15.19s2, clone 15.19s2, Upstate®, from mouse